Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Although survival rates have significantly improved over the past few decades, 20–30% of children will succumb due to treatment-related toxicity or relapse. The molecular characterization of the leukemic stem cell, shown to be responsible for relapse, is needed to improve treatment options and survival. Recently, it has become clear that non-coding RNAs, including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), play a role in the development of human diseases, including pediatric cancer. Nevertheless, non-coding RNA expression data in pedAML are scarce. Here, we explored lncRNA (n = 30,168) and miRNA (n = 627) expression in pedAML subpopu...
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as...
Acute myeloid leukemia (AML) is caused by malignant transformation of hematopoietic stem or progenit...
BackgroundStill 30–40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation of...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
Abstract Background LncRNAs can regulate miRNAs and mRNAs by sequestering and binding them. Indeed, ...
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Acute myeloid leukemia (AML) is a common hematological disorder with heterogeneous nature that resul...
textabstractBackground MicroRNA regulate the activity of protein-coding genes including those involv...
Recent analyses have shown that human cells transcribe almost their entire genomes, implying the exi...
Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic cells in the...
MicroRNAs (miRNAs) regulate the expression of protein-coding genes and represent potential biomarker...
Background: To establish a comprehensive differential gene profile for pediatric acute myeloid leuke...
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric neoplasia. Highly heterogene...
Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regu...
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as...
Acute myeloid leukemia (AML) is caused by malignant transformation of hematopoietic stem or progenit...
BackgroundStill 30–40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation of...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
Abstract Background LncRNAs can regulate miRNAs and mRNAs by sequestering and binding them. Indeed, ...
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Acute myeloid leukemia (AML) is a common hematological disorder with heterogeneous nature that resul...
textabstractBackground MicroRNA regulate the activity of protein-coding genes including those involv...
Recent analyses have shown that human cells transcribe almost their entire genomes, implying the exi...
Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic cells in the...
MicroRNAs (miRNAs) regulate the expression of protein-coding genes and represent potential biomarker...
Background: To establish a comprehensive differential gene profile for pediatric acute myeloid leuke...
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric neoplasia. Highly heterogene...
Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regu...
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as...
Acute myeloid leukemia (AML) is caused by malignant transformation of hematopoietic stem or progenit...
BackgroundStill 30–40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation of...